Mixed ductal-endocrine carcinoma of the pancreas presenting as gastrinoma with Zollinger-Ellison syndrome: an autopsy case with a 24-year survival period.
We report an autopsy case of mixed ductal-endocrine carcinoma of the pancreas presenting as gastrinoma with Zollinger-Ellison syndrome. A 38-year-old Japanese male was found to have Zollinger-Ellison syndrome and pancreatic gastrinoma, and gastrectomy and resection of the pancreatic tumor were performed. However, hypergastrinemia persisted, and the patient died of disseminated carcinomatosis at 62 years of age, 24 years after the onset of Zollinger-Ellison syndrome. At autopsy, the main tumor was present in the residual pancreas, and metastases were noted in many organs. In the pancreas and other organs, ductal and endocrine carcinoma areas were mixed and there was a gradual transition between the two. No acinar differentiation was noted. The ductal elements were positive for mucins and carcinoembryonic antigen but negative for neuroendocrine markers, while endocrine elements were positive for chromogranin A and synaptophysin and to a lesser extent for gastrin, but negative for mucins and carcinoembryonic antigen. The ductal elements comprised about 30% of the tumor cells, and endocrine elements 70%. According to the revised World Health Organization classification, our case was diagnosed as mixed ductal-endocrine carcinoma. Our case is rare because the tumor manifested as gastrinoma with Zollinger-Ellison syndrome and the patient survived for 24 years. To the best of our knowledge, no such case has been reported. Our case suggests that pancreatic endocrine tumors may evolve into mixed ductal-endocrine carcinomas.
Terada
T
T
Second Department of Pathology, Faculty of Medicine, Tottori University, Japan.
Matsunaga
Y
Y
Maeta
H
H
Endo
K
K
Horie
S
S
Ohta
T
T
D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis; D018395:CA-19-9 Antigen / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry / Q000175:diagnosis*; D018273:Carcinoma, Islet Cell / Q000737:chemistry / Q000175:diagnosis*; D053379:Chromogranin A; D002864:Chromogranins / Q000032:analysis; D003937:Diagnosis, Differential; D004701:Endocrine Gland Neoplasms; D017809:Fatal Outcome; D015408:Gastrinoma / Q000737:chemistry / Q000175:diagnosis*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000032:analysis; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000175:diagnosis*; D016708:Synaptophysin / Q000032:analysis; D015043:Zollinger-Ellison Syndrome / Q000175:diagnosis*
D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D053379:Chromogranin A; D002864:Chromogranins; D009077:Mucins; D016708:Synaptophysin